Balchem Corporation Stock

$154.82

2.24% today

Nasdaq, Jul 18, 06:13 pm CET

ISIN

US0576652004

Symbol

BCPC

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P SmallCap 600

Sector

Process industry

Industry

Chemistry

Overview Dividends Analysts Charts News Strategies

Balchem Corporation Stock price

$158.37

+58.66 58.83% 5Y

Nasdaq, Closing price Thu, Jul 17 2025

+0.23 0.15%

ISIN

US0576652004

Symbol

BCPC

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P SmallCap 600

Sector

Process industry

Industry

Chemistry

Key metrics

Basic

Market capitalization

$5.2b

Enterprise Value

$5.3b

Net debt

$142.0m

Cash

$49.9m

Shares outstanding

32.6m

Valuation (TTM | estimate)

P/E

38.0 | 30.6

P/S

5.4 | 5.0

EV/Sales

5.5 | 5.1

EV/FCF

35.2

P/B

4.3

Dividends

DPS

$0.87

Yield 1Y | 5Y

0.6% | 0.5%

Growth 1Y | 5Y

10.1% | 10.8%

Payout 1Y | 3Y

22.1% | 22.5%

Increased

15 Years

Financials (TTM | estimate)

Revenue

$964.5m | $1.0b

EBITDA

$237.6m | $269.9m

EBIT

$192.2m | $211.6m

Net Income

$136.5m | $168.8m

Free Cash Flow

$150.8m

Growth (TTM | estimate)

Revenue

3.8% | 8.7%

EBITDA

7.3% | 16.3%

EBIT

15.5% | 15.0%

Net Income

18.9% | 31.4%

Free Cash Flow

2.4%

Financial Health

Equity Ratio

73.0%

Return on Equity

11.2%

ROCE

13.0%

ROIC

9.9%

Debt/Equity

0.2

EPS

$4.2

FCF per Share

$4.6

Short interest

2.0%

Employees

Rev per Employee

$690.0k

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Get Started for Free Today

Balchem Corporation Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Balchem Corporation forecast:

7x Buy

88%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Balchem Corporation forecast:

Buy

88%

Hold

13%

Analyst Estimates with Stock Price Targets

Financial data from Balchem Corporation

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	965 965	4% 4% 100%
- Direct Costs	622 622	0% 0% 64%
Gross Profit	343 343	10% 10% 36%
- Selling and Administrative Expenses	132 132	0% 0% 14%
- Research and Development Expense	17 17	10% 10% 2%
EBITDA	238 238	7% 7% 25%
- Depreciation and Amortization	45 45	18% 18% 5%
EBIT (Operating Income) EBIT	192 192	16% 16% 20%
Net Profit	137 137	19% 19% 14%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Balchem Corporation Stock News

Neutral

GlobeNewsWire

●

one day ago

Balchem Corporation Announces Quarterly Conference Call for Second Quarter 2025 Financial Results on July 31, 2025

MONTVALE, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today announced that a conference call will be held on Thursday, July 31, 2025, at 11:00 AM Eastern Time (ET) to review second quarter 2025 results.

Positive

Seeking Alpha

●

4 days ago

Balchem Corporation: The Next Earnings Release Should Guide Investors

Balchem operates in diverse specialty ingredient markets, maintaining steady growth and a market cap of $5.3B. Revenue per share has grown 6% annually over a decade, but recent growth has plateaued, warranting close monitoring. Gross profit margin has improved significantly, rising from 30% to over 35% in the latest fiscal year.

Neutral

GlobeNewsWire

●

22 days ago

Balchem Corporation to Present at the CJS Annual New Ideas Summer Conference on July 10, 2025

MONTVALE, N.J., June 26, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at the CJS Annual New Ideas Summer Conference on July 10, 2025.

More Balchem Corporation News

Company Profile

marketing of specialty performance ingredients and products. It operates through the following segments: Human Nutrition and Health, Animal Nutrition and Health, Specialty Products and Industrial Products. The Human Nutrition and Health segment supplies ingredients in the food and beverage industry, providing customized solutions in powder, solid and liquid flavor delivery systems, spray dried emulsified powder systems, and cereal systems. The Animal Nutrition and Health segment comprises nutritional products derived from microencapsulation and chelation technologies in addition to basic choline chloride. The Specialty Products segment offers Ethylene oxide for the health care industry. The Industrial Products segment refers to certain derivatives of choline chloride which manufactured and sold into industrial applications as a component for hydraulic fracturing of shale natural gas wells. The company was founded in January 1967 and is headquartered in New Hampton, NY.

Head office	United States
CEO	Theodore Harris
Employees	1,379
Founded	1967
Website	balchem.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now